Pharmaceutical Biotechnology and Biotechnological/Biological Medicinal Products

• Recombinant DNA technology, production of recombinant drugs and vaccines, upstream/downstream processes
• Preformulation, formulation, and preclinical evaluation of recombinant drugs and vaccines
• Pharmaceutical quality assurance (good manufacturing practices, quality control, and quality risk management) and risk-based licensing in biotechnological/biological drugs (recombinant proteins, monoclonal antibodies, biosimilar drugs, vaccines (protein-, DNA-, mRNA-, and viral vector-based vaccines), immunopharmaceuticals, immunotherapeutics, stem cell-based drugs, advanced therapy medicinal products (ATMPs) (somatic cell therapy medicinal products, gene therapy medicinal products, tissue-engineered products, combined ATMPs)), orphan drugs, personalized medicines, regenerative medicine advanced therapies, gene therapy, and biotechnological/biological drug–medical device combination products; clinical research; ethical/bioethical principles; and national/international legal regulations and legislation
• National/international pharmacopoeias and biotechnological/biological drugs

Pharmaceutical Biotechnology and Cell Culture Studies

• Bacterial culture, preparation of competent bacteria, plasmid DNA amplification and purification
• Isolation of bacterial DNA, gene acquisition by polymerase chain reaction, cloning into plasmids, and bacterial transformation
• Production, purification, and characterization of recombinant proteins in bacteria
• Mammalian cell culture, human pluripotent stem cell and induced pluripotent stem cell culture
• Cell viability and cytotoxicity assays; transepithelial/transendothelial electrical resistance, transport, and microscopic analyses in biological barriers
• Genomics, functional genomics, and bioinformatics in predictive toxicity studies of biotechnological/biological medicinal products and innovative drugs

Pharmaceutical Biotechnology and Bionanotechnology

• Drug, vaccine, gene, and cellular delivery systems, liquid crystals, micellar systems, liposomes, and lipid-based carrier systems (lipid prodrugs, lipid micropellets, solid lipid nanoparticles, lipid micropellets and nanoparticles); formulation design, characterization, and analyses

Drug, Gene, and Cellular Delivery Systems

• Drug, gene, and cellular delivery systems; formulation design, characterization, and analyses; in vivo and in vitro studies on the safe application of oral, parenteral, ocular, intraocular, and retinal delivery systems; their pharmacokinetic properties, biodistribution and fate, interactions with biological fluids, cellular toxicity in target organs, and in vitro models (blood–retina barrier model with retinal pigment epithelial cells and retinal toxicity, renal tubular epithelial cell cultures and nephrotoxicity), and nanotoxicology